Cargando…

692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States

BACKGROUND: In 2020, the FDA approved fidaxomicin (FDX) for the treatment of Clostridioides difficile infection (CDI) in children 6 months and older. The latest IDSA/SHEA guidelines recommend FDX use for adults only. A survey presented at IDWeek 2022 showed that only 35% of institutions used FDX as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yuman, Bradley, Nicole, Smith, Sarah, Rakhimova, Shakhzoda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679036/ http://dx.doi.org/10.1093/ofid/ofad500.754

Ejemplares similares

392. Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States
por: Basir, Angela, et al.
Publicado: (2022)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study
por: Alsoubani, Majd, et al.
Publicado: (2023)

669. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience
por: Alsoubani, Majd, et al.
Publicado: (2023)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France
por: Guery, Benoit, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

2404. Molecular Epidemiology of Clostridioides difficile in the United States, 2017
por: Paulick, Ashley, et al.
Publicado: (2019)

692. Effects of Regional Climatic Variability on West Nile Virus Outbreaks in the United States
por: Kangath, Raghesh Varot, et al.
Publicado: (2018)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

PT692. Pain, Anxiety and their relationship with Dose of Medications in Intensive Care Unit
por: Park, Sunyoung, et al.
Publicado: (2016)

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis
por: Brauer, Madita, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

467 Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections
por: Flaherty, Sarah, et al.
Publicado: (2014)

Fidaxomicin for the Treatment of Clostridium Difficile Infection in the Pediatric Population - Not Quite So Soon Yet
por: Daniels, Tanya, et al.
Publicado: (2011)

2376. Incidence of Clostridioides difficile Infection Among United States Medicare Advantage Enrollees
por: Heinrich, Kirstin, et al.
Publicado: (2019)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

500. Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection With History of Multiple Recurrences
por: Lee, Christine, et al.
Publicado: (2018)

1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System
por: Bariola, J Ryan, et al.
Publicado: (2019)

2368. Molecular Epidemiology of Clostridioides difficile Infections in Pediatric Oncology and Transplant Patients
por: Barbar, Ruba, et al.
Publicado: (2019)

1710. Clostridioides difficile Bundle Implementation Reduces Unnecessary Testing in Pediatric Patients
por: Sietsema, Lydia, et al.
Publicado: (2023)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
por: Mori, Nobuaki, et al.
Publicado: (2023)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

2383. Epidemiological and Clinical Features of Clostridioides difficile Infections in Pediatric Oncology and Transplant Patients
por: Barbar, Ruba, et al.
Publicado: (2019)

1663. Clostridioides difficile testing following 18706 Pediatric Procedures: Implications for Diagnostic Stewardship
por: Negi, Ruchita, et al.
Publicado: (2023)

692. Coccidioides sp. Infective Endocarditis: A Review of the Literature
por: Kasule, Sabirah N, et al.
Publicado: (2021)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

529. Overdiagnosis of Clostridioides difficile with a Multiplex PCR Panel
por: Arora, Vaneet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hdd81rhtmnis96si2si5ucrep0